人乳头瘤病毒与子宫颈癌临床关系研究进展

[1] HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives[J] . Xavier Castellsagué,Achim Schneider,Andreas M. Kaufmann,F. Xavier Bosch.Gynecologic Oncology . 2009 (3)

[2] Innovation in Cervical Cancer Prevention and Control in Mexico [J]. ARCHIVES OF MEDICAL RESEARCH, 2009, 40 (06) : 486 - 492

[3] Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis[J] . The Lancet Infectious Diseases . 2007 (7)

[4] Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)

[5] Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial[J] . Luisa L Villa,Ronaldo LR Costa,Carlos A Petta,Rosires P Andrade,Kevin A Ault,Anna R Giuliano,Cosette M Wheeler,Laura A Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven-Eric Olsson,Margareta Steinwall,Darron R Brown,Robert J Kurman,Brigitte M Ronnett,Mark H Stoler,Alex Ferenczy,

[6] Cervical cancer vaccines available in 2007 [J]. DRUG DISCOVERY TODAY, 2005, 10 (14) : 949 - 950

[7] Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis[J] . The Lancet . 2005 (9490)

[8] Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study[J] . Ciaran BJ Woodman,Stuart Collins,Heather Winter,Andrew Bailey,John Ellis,Pat Prior,Marie Yates,Terry P Rollason,Lawrence S Young.The Lancet . 2001 (9271)

[1] HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives[J] . Xavier Castellsagué,Achim Schneider,Andreas M. Kaufmann,F. Xavier Bosch.Gynecologic Oncology . 2009 (3)

[2] Innovation in Cervical Cancer Prevention and Control in Mexico [J]. ARCHIVES OF MEDICAL RESEARCH, 2009, 40 (06) : 486 - 492

[3] Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis[J] . The Lancet Infectious Diseases . 2007 (7)

[4] Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial[J] . Diane M Harper,Eduardo L Franco,Cosette M Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia M Roteli-Martins,David Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin.The Lancet . 2006 (9518)

[5] Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial[J] . Luisa L Villa,Ronaldo LR Costa,Carlos A Petta,Rosires P Andrade,Kevin A Ault,Anna R Giuliano,Cosette M Wheeler,Laura A Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven-Eric Olsson,Margareta Steinwall,Darron R Brown,Robert J Kurman,Brigitte M Ronnett,Mark H Stoler,Alex Ferenczy,

[6] Cervical cancer vaccines available in 2007 [J]. DRUG DISCOVERY TODAY, 2005, 10 (14) : 949 - 950

[7] Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis[J] . The Lancet . 2005 (9490)

[8] Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study[J] . Ciaran BJ Woodman,Stuart Collins,Heather Winter,Andrew Bailey,John Ellis,Pat Prior,Marie Yates,Terry P Rollason,Lawrence S Young.The Lancet . 2001 (9271)